Endothelin A antagonist LU-135252 and trandolapril in the treatment of the Cohen-Rosenthal diabetic hypertensive rat.

Background. Hypertension and non‐insulin‐dependent diabetes mellitus (NIDDM) often occur simultaneously and the combination requires vigorous control of hypertension. This can generally be achieved by a combination of antihypertensive drugs. The present study examines the antihypertensive and possible hypoglycemic effects of combined therapy with endothelin A (ETA) receptor antagonist LU‐135252 and angiotensin‐converting enzyme (ACE) inhibitor trandolapril in male Cohen–Rosenthal Diabetic Hypertensive (CRDH) rats. Methods. Rats were divided into four groups as follows: group I served as control; group II – LU‐135252 30 mg/kg/day; group III – trandolapril 0.1 mg/kg/day and group IV – both LU‐135252 30 mg/kg/day and trandolapril 0.1 mg/kg/day. Systolic blood pressure (SBP) and plasma glucose levels were evaluated at the beginning of the experiment and after 2, 4 and 6 weeks. Results. SBP decreased significantly in all treated groups after 2, 4 and 6 weeks of treatment compared to baseline. Maximum decrease ...